Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts.

Verel I, Heider KH, Siegmund M, Ostermann E, Patzelt E, Sproll M, Snow GB, Adolf GR, van Dongen GA.

Int J Cancer. 2002 May 20;99(3):396-402.

2.

Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.

Börjesson PK, Postema EJ, Roos JC, Colnot DR, Marres HA, van Schie MH, Stehle G, de Bree R, Snow GB, Oyen WJ, van Dongen GA.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3961S-72S.

3.

Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients.

Stroomer JW, Roos JC, Sproll M, Quak JJ, Heider KH, Wilhelm BJ, Castelijns JA, Meyer R, Kwakkelstein MO, Snow GB, Adolf GR, van Dongen GA.

Clin Cancer Res. 2000 Aug;6(8):3046-55.

4.

Rapid elimination of mouse/human chimeric monoclonal antibodies in nude mice.

van Gog FB, Brakenhoff RH, Snow GB, van Dongen GA.

Cancer Immunol Immunother. 1997 Apr;44(2):103-11.

PMID:
9177472
5.

Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.

Verel I, Visser GW, Boerman OC, van Eerd JE, Finn R, Boellaard R, Vosjan MJ, Stigter-van Walsum M, Snow GB, van Dongen GA.

Cancer Biother Radiopharm. 2003 Aug;18(4):655-61.

PMID:
14503961
6.

Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck.

Colnot DR, Roos JC, de Bree R, Wilhelm AJ, Kummer JA, Hanft G, Heider KH, Stehle G, Snow GB, van Dongen GA.

Cancer Immunol Immunother. 2003 Sep;52(9):576-82.

PMID:
14627130
7.

111In-Labeled anti-CD44v6 chimeric monoclonal antibody U36 .

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2008 Jul 22 [updated 2008 Aug 14].

8.

MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck.

Schrijvers AH, Quak JJ, Uyterlinde AM, van Walsum M, Meijer CJ, Snow GB, van Dongen GA.

Cancer Res. 1993 Sep 15;53(18):4383-90.

9.

Humanized anti-CD44v6 monoclonal antibody labeled with IRDye800CW.

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2013 May 20 [updated 2013 Jun 28].

10.

Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.

Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA.

J Nucl Med. 2006 Jul;47(7):1127-35.

11.

A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio.

Sandström K, Haylock AK, Spiegelberg D, Qvarnström F, Wester K, Nestor M.

Int J Oncol. 2012 May;40(5):1525-32. doi: 10.3892/ijo.2012.1352. Epub 2012 Feb 1.

PMID:
22307465
12.

Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer.

Brakenhoff RH, van Gog FB, Looney JE, van Walsum M, Snow GB, van Dongen GA.

Cancer Immunol Immunother. 1995 Mar;40(3):191-200.

PMID:
7728778
13.

Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer.

Koppe M, Schaijk Fv, Roos J, Leeuwen Pv, Heider KH, Kuthan H, Bleichrodt R.

Cancer Biother Radiopharm. 2004 Dec;19(6):720-9.

PMID:
15665619
14.

Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform.

Van Hal NL, Van Dongen GA, Rood-Knippels EM, Van Der Valk P, Snow GB, Brakenhoff RH.

Int J Cancer. 1996 Nov 15;68(4):520-7.

15.

Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies.

Fortin MA, Salnikov AV, Nestor M, Heldin NE, Rubin K, Lundqvist H.

Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1376-87. Epub 2007 Feb 3.

PMID:
17277931
16.

Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.

Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ, Huijgens PC, Snow GB, van Dongen GA.

J Nucl Med. 2000 Dec;41(12):1999-2010.

17.

Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.

Verel I, Visser GW, Boellaard R, Boerman OC, van Eerd J, Snow GB, Lammertsma AA, van Dongen GA.

J Nucl Med. 2003 Oct;44(10):1663-70.

18.

Targeting CD44v6 expressed in head and neck squamous cell carcinoma: preclinical characterization of an 111In-labeled monoclonal antibody.

Sandström K, Nestor M, Ekberg T, Engström M, Anniko M, Lundqvist H.

Tumour Biol. 2008;29(3):137-44. doi: 10.1159/000143399. Epub 2008 Jul 9.

PMID:
18612218
19.

Targeting of aluminum (III) phthalocyanine tetrasulfonate by use of internalizing monoclonal antibodies: improved efficacy in photodynamic therapy.

Vrouenraets MB, Visser GW, Stigter M, Oppelaar H, Snow GB, van Dongen GA.

Cancer Res. 2001 Mar 1;61(5):1970-5.

20.

Comparison of tumor targeting in nude mice by murine monoclonal antibodies directed against different human colorectal cancer antigens.

Sharkey RM, Gold DV, Aninipot R, Vagg R, Ballance C, Newman ES, Ostella F, Hansen HJ, Goldenberg DM.

Cancer Res. 1990 Feb 1;50(3 Suppl):828s-834s.

Supplemental Content

Support Center